129 related articles for article (PubMed ID: 22785500)
1. The influence of residual nor-β-CFT in 11C CFT injection on the Parkinson disease diagnosis: a 11C CFT PET study.
Huang T; Wang H; Tang G; Liang X; Shi X; Zhang X
Clin Nucl Med; 2012 Aug; 37(8):743-7. PubMed ID: 22785500
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease.
Li X; Zhang Q; Qin Y; Li Y; Mutaerbieke N; Zhao X; Yibulayin A
Medicine (Baltimore); 2020 Apr; 99(14):e19662. PubMed ID: 32243399
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis.
Jiang L; Wang X; Li P; Feng Z; Shi X; Shao H
Medicine (Baltimore); 2020 Dec; 99(51):e23395. PubMed ID: 33371068
[TBL] [Abstract][Full Text] [Related]
5. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Ruottinen H; Ruotsalainen U; Rinne UK
Synapse; 1995 Oct; 21(2):97-103. PubMed ID: 8584980
[TBL] [Abstract][Full Text] [Related]
6. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
7. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
8. Cocaine congeners as PET imaging probes for dopamine terminals.
Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
[TBL] [Abstract][Full Text] [Related]
9. [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats.
Haaparanta M; Bergman J; Laakso A; Hietala J; Solin O
Synapse; 1996 Aug; 23(4):321-7. PubMed ID: 8855517
[TBL] [Abstract][Full Text] [Related]
10. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
[TBL] [Abstract][Full Text] [Related]
11. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
12. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
Rinne JO; Bergman J; Ruottinen H; Haaparanta M; Eronen E; Oikonen V; Sonninen P; Solin O
Synapse; 1999 Feb; 31(2):119-24. PubMed ID: 10024008
[TBL] [Abstract][Full Text] [Related]
13. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
[TBL] [Abstract][Full Text] [Related]
14. Effects of hypoxic-ischemic brain injury on striatal dopamine transporter in newborn piglets: evaluation of 11C-CFT PET/CT for DAT quantification.
Zhang YF; Wang XY; Cao L; Guo QY; Wang XM
Nucl Med Biol; 2011 Nov; 38(8):1205-12. PubMed ID: 21741256
[TBL] [Abstract][Full Text] [Related]
15. Competition between 11C-raclopride and endogenous dopamine in Parkinson's disease.
Ishibashi K; Ishii K; Oda K; Mizusawa H; Ishiwata K
Nucl Med Commun; 2010 Feb; 31(2):159-66. PubMed ID: 19966595
[TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter binding in rat striatum: a comparison of [O-methyl-11C]beta-CFT and [N-methyl-11C]beta-CFT.
Yoder KK; Hutchins GD; Mock BH; Fei X; Winkle WL; Gitter BD; Territo PR; Zheng QH
Nucl Med Biol; 2009 Jan; 36(1):11-6. PubMed ID: 19181264
[TBL] [Abstract][Full Text] [Related]
17. SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
Fischman AJ; Babich JW; Elmaleh DR; Barrow SA; Meltzer P; Hanson RN; Madras BK
J Nucl Med; 1997 Jan; 38(1):144-50. PubMed ID: 8998169
[TBL] [Abstract][Full Text] [Related]
18. Suite PET/CT neuroimaging for the diagnosis of Parkinson's disease: statistical parametric mapping analysis.
Wang R; Xu B; Guo Z; Chen T; Zhang J; Chen Y; Zhu H
Nucl Med Commun; 2017 Feb; 38(2):164-169. PubMed ID: 27893588
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 2beta-carbomethoxy-3beta-(4-[18F]fluorophenyl)tropane and N-(3-[18F]fluoropropyl)-2beta-carbomethoxy-3beta-(4-fluorophenyl)nortropane, tracers for imaging dopamine transporter in rat.
Marjamäki P; Haaparanta M; Forsback S; Fagerholm V; Eskola O; Grönroos T; Koivula T; Solin O
Mol Imaging Biol; 2010 Jun; 12(3):269-77. PubMed ID: 19949983
[TBL] [Abstract][Full Text] [Related]
20. Ketamine alters the availability of striatal dopamine transporter as measured by [(11)C]beta-CFT and [(11)C]beta-CIT-FE in the monkey brain.
Tsukada H; Nishiyama S; Kakiuchi T; Ohba H; Sato K; Harada N
Synapse; 2001 Dec; 42(4):273-80. PubMed ID: 11746726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
